The role of gene regulatory networks in promoting cancer progression and metastasis

Future Oncology

Volumn 10, Issue 5, 2014, Pages 735-748

  Coghlin, Caroline ^a   Murray, Graeme I ^b  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

cancer; gene regulatory network; metastasis; progression; systems biology

Indexed keywords

CANCER CELL; CANCER GROWTH; CANCER MORTALITY; CONCEPTUAL FRAMEWORK; DORMANCY; GENE REGULATORY NETWORK; HUMAN; HYPOTHESIS; MEDICAL RESEARCH; METASTASIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC DISEASE; TUMOR MICROENVIRONMENT; DISEASE COURSE; GENETICS; PATHOLOGY;

DISEASE PROGRESSION; GENE REGULATORY NETWORKS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS;

EID: 84899809569     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.264     Document Type: Review

References (104)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics 2008. CA Cancer J. Clin. 58, 71-96 (2008).
2. Folkman J, Kalluri R. Cancer without disease. Nature 427, 787 (2004).
3. Rice J. Metastasis: the rude awakening. Nature 485, S55-S57 (2012).
4. Coghlin C, Murray GI. Current and emerging concepts in tumour metastasis. J. Pathol. 222, 1-15 (2010).
5. Seton-Rogers S. Metastasis: navigating uncharted territory. Nat. Rev. Cancer 12, 151 (2012).
6. Bizzarri M, Giuliani A, D'Anselmi F, Soto AM, Sonnenschein C. Fractal analysis in a systems biology approach to cancer. Semin. Cancer Biol. 21, 175-182 (2011).
7. Huang S. On the intrinsic inevitability of cancer: from foetal to fatal attraction. Semin. Cancer Biol. 21, 183-199 (2011).
8. Huang S, Ernberg I, Kauffman S. Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. Semin. Cell Dev. Biol. 20, 869-876 (2009).
9. Zhang Y, Moriguchi H. Chromatin remodeling system, cancer stem-like attractors and cellular reprogramming. Cell. Mol. Life Sci. 68, 3557-3571 (2011).
10. Naumov GN, Folkman J, Straume O. Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clin. Exp. Metastasis 26, 51-60 (2009).
11. Paez D, Labonte MJ, Bohanes P et al. Cancer dormancy: a model of early dissemination and late cancer recurrence. Clin. Cancer Res. 18, 645-653 (2012).
12. Olsen O, Gøtzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet 358, 1340-1342 (2001).
13. Jørgensen KJ, Brodersen J, Gøtzsche PC. Thirteen years of breast screening had no measurable effect on breast cancer mortality in Norway. Int. J. Cancer 132, 1725-1726 (2013).
14. Gøtzsche PC, Jørgensen KJ, Zahl PH, Mæhlen J. Why mammography screening has not lived up to expectations from the randomised trials. Cancer Causes Contro. 23, 15-21 (2012).
15. Zahl PH, Gøtzsche PC, Mæhlen J. Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study. Lancet Oncol. 12, 1118-1124 (2011).
16. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst. Rev. 1, CD001877 (2011).
17. Retsky M, Demicheli R, Hrushesky W, Baum M, Gukas I. Surgery triggers outgrowth of latent disease in breast cancer: an inconvenient truth? Cancers 2, 305-337 (2010).
18. Demicheli R, Biganzoli E, Boracchi P, Greco M, Retsky MW. Recurrence dynamics does not depend on the recurrence site. Breast Cancer Res. 10, R83 (2008).
19. Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID. The effects of surgery on tumor growth: a century of investigations. Ann. Oncol. 19, 1821-1828 (2008).
20. Retsky MW, Demicheli R, Hrushesky WJ, Baum M, Gukas ID. Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer. APMIS 116, 730-741 (2008).
21. Demicheli R, Retsky MW, Hrushesky WJ, Baum M. Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat. Clin. Pract. Oncol. 4, 699-710 (2007).
22. Demicheli R, Miceli R, Moliterni A et al. Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol. 16, 1449-1457 (2005).
23. Baum M, Demicheli R, Hrushesky W, Retsky M. Does surgery unfavourably perturb the 'natural history' of early breast cancer by accelerating the appearance of distant metastases? Eur. J. Cancer 41, 508-515 (2005).
24. Retsky M, Demicheli R, Hrushesky W. Wounding from biopsy and breast-cancer progression. Lancet 357, 1048 (2001).
25. Retsky M, Demicheli R, Hrushesky W. Premenopausal status accelerates relapse in node positive breast cancer: hypothesis links angiogenesis, screening controversy. Breast Cancer Res. Treat. 65, 217-224 (2001).
26. Hanin LG. Why victory in the war on cancer remains elusive: biomedical hypotheses and mathematical models. Cancers 3, 340-367 (2011).
27. Retsky M, Bonadonna G, Demicheli R, Folkman J, Hrushesky W, Valagussa P. Hypothesis: induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients. Breast Cancer Res. 6, R372-R374 (2004).
28. Nielsen M, Thomsen, JL, Primdahl S, Dyoreborg U, Andersen JA. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br. J. Cancer 56, 814-819 (1987).
29. Welch GH, Black WC. Overdiagnosis in cancer. J. Natl Cancer Inst. 102, 605-613 (2010).
30. Welch GH, Black WC. Using autopsy studies to estimate the disease 'reservoir' for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann. Intern. Med. 127, 1023-1028 (1997).
31. Vickers AJ, Roobol MJ, Lilja H. Screening for prostate cancer: early detection or overdetection? Annu. Rev. Med. 63, 161-170 (2012).
32. Hoffman RM. Clinical practice. Screening for prostate cancer. N. Engl. J. Med. 365, 2013-2019 (2011).
33. Jatoi I. Options in breast cancer local therapy: who gets what? World J. Surg. 36, 1498-1502 (2012).
34. Wilt TJ, Brawer MK, Jones KM et al. Radical prostatectomy versus observation for localized prostate cancer. N. Engl. J. Med. 367, 203-213 (2012).
35. Parker C. Treating prostate cancer. BMJ 345, e5122 (2012).
36. Bernards R, Weinberg RA. A progression puzzle. Nature 418, 823 (2002).
37. Weinberg RA. Leaving home early: re-examination of the canonical models of tumour progression. Cancer Cell 14, 283-284 (2008).
38. Fisher B. Laboratory and clinical research in breast cancer: a personal adventure: the David A. Karnofsky memorial lecture. Cancer Res. 40, 3863-3874 (1980).
39. van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
40. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
41. Weigelt B, Hu Z, He X et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 65, 9155-9158 (2005).
42. Mook S, Knauer M, Bueno-de-Mesquita JM et al. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. Ann Surg Oncol 17, 1406-1413 (2010).
43. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869-10874 (2001).
44. Huang S. The molecular and mathematical basis of Waddington's epigenetic landscape: a framework for post-Darwinian biology? Bioessays 34, 149-157 (2012).
45. Wang J, Zhang K, Xu L, Wang E. Quantifying the Waddington landscape and biological paths for development and differentiation. Proc. Natl Acad. Sci. USA 108, 8257-8262 (2011).
46. Kaneko K. Characterization of stem cells and cancer cells on the basis of gene expression profile stability, plasticity, and robustness. Bioessays 33, 403-413 (2011).
47. Davies PC, Lineweaver CH. Cancer tumours as Metazoa 1.0: tapping genes of ancient ancestors. Phys. Biol. 8, 1-7 (2011).
48. Brock A, Chang H, Huang S. Non-genetic heterogeneity -A mutation-independent driving force for the somatic evolution of tumours. Nat. Rev. Genet. 10, 336-342 (2009).
49. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat. Rev. Cancer 12, 323-334 (2012).
50. Almendro V, Marusyk A, Polyak K. Cellular heterogeneity and molecular evolution in cancer. Annu. Rev. Pathol. 8, 277-302 (2013).
51. Chang HH, Hemberg M, Barahona M, Ingber DE, Huang S. Transcriptome-wide noise controls lineage choice in mammalian progenitor cells. Nature 453, 544-547 (2008).
52. Prehn RT. The role of mutation in the new cancer paradigm. Cancer Cell Int. 5, 9 (2005).
53. Prehn RT. Cancers beget mutations versus mutations beget cancers. Cancer Res. 54, 5296-5300 (1994).
54. Rubin H. What keeps cells in tissues behaving normally in the face of myriad mutations? Bioessays 28, 515-524 (2006).
55. Larson PS, de las Morenas A, Cupples LA, Huang K, Rosenburg CL. Genetically abnormal clones in histologically normal breast tissue. Am J. Pathol. 152, 1591-1598 (1998).
56. Scheel C, Weinberg RA. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin. Cancer Biol. 22, 396-403 (2012).
57. Sonnenschein C, Soto AM. The death of the cancer cell. Cancer Res. 71, 4334-4337 (2011).
58. Sonnenschein C, Soto AM. The Society of Cells: Cancer and Control of Cell Proliferation. Springer Verlag, NY, USA (1999).
59. Soto AM, Sonnenschein C. The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory. Bioessays 33, 332-340 (2011).
60. Huang S, Ingber DE. A non-genetic basis for cancer progression and metastasis: self-organizing attractors in cell regulatory networks. Breast Dis. 26, 27-54 (2007).
61. Demicheli R, Coradini D. Gene regulatory networks: a new conceptual framework to analyse breast cancer behaviour. Ann. Oncol. 22, 1259-1265 (2011).
62. Gudjonsson T, Rønnov-Jessen L, Villadsen R, Rank F, Bissell MJ, Petersen OW. Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. J. Cell Sci. 115, 39-50 (2002).
63. Sleeman JP, Christofori G, Fodde R et al. Concepts of metastasis flux: the stromal progression model. Semin. Cancer Biol. 22, 174-186 (2012).
64. Enderling H, Hahnfeldt P, Hlatky L, Almog N. Systems biology of tumor dormancy: linking biology and mathematics on multiple scales to improve cancer therapy. Cancer Res. 72, 2172-2175 (2012).
65. Scott J, Kuhn P, Anderson ARA. Unifying metastasis-integrating intravasation, circulation and end-organ colonization. Nat. Rev. Cancer 12, 445-446 (2012).
66. Husemann Y, Geigl JB, Schubert F et al. Systemic spread in early breast cancer. Cancer Cell 13, 58-68 (2008).
67. Rhim AD, Mirek ET, Aiello NM et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349-361 (2012).
68. Tuveson DA, Neoptolemos JP. Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell 148, 21-23 (2012).
69. Schmidt-Kittler O, Rag T, Daskalakis A et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc. Natl Acad. Sci. USA 100, 7737-7742 (2003).
70. Bidard F-C, Pierga J-Y, Vincent-Salomon A, Poupon MF. A 'class action against the microenvironment: do cancer cells cooperate in metastasis? Cancer Metastasis Rev. 27, 5-10 (2008).
71. Wu JM, Fackler MJ, Haluska MK et al. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin. Cancer Res. 14, 1938-1946 (2008).
72. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100, 57-70 (2000).
73. Weinberg RA, Hananhan D. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
74. Kaplan RN, Riba RD, Zacharoulis S et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 438, 821-827 (2005).
75. Kaplan RN, Psaila B, Lyden D. Bone marrow cells in the 'premetastatic niche': within bone and beyond. Cancer Metastasis Rev. 25, 521-529 (2006).
76. Kaplan RN, Rafii S, Lyden D. Preparing the 'soil': the premetastatic niche. Cancer Res. 66, 11089-11093 (2006).
77. McAllister SS, Gifford AM, Greiner AL et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 133, 994-1005 (2008).
78. Ruggiero RA, Bruzzo J, Chiarella P, Bustuoabad OD, Meiss RP, Pasqualini CD. Concomitant tumor resistance: the role of tyrosine isomers in the mechanisms of metastases control. Cancer Res. 72, 1043-1050 (2012).
79. Prehn RT. Two competing influences that may explain concomitant tumor resistance. Cancer Res. 53, 3266-3269 (1993).
80. Folkman J, Hahnfeldt P, Hlatky L. Cancer: looking outside the genome. Nat. Rev. Mol. Cell Biol. 1, 76-79 (2000).
81. Schaefer C, Schroeder M, Fuhrhop I et al. Primary tumor dependent inhibition of tumor growth, angio-genesis and perfusion of secondary breast cancer in bone. J. Orthop. Res. 29, 1251-1258 (2011).
82. Strauss DC, Thomas JM. Transmission of donor melanoma by organ transplantation. Lancet Oncol. 11, 790-796 (2010).
83. Penn I. Donor transmitted disease: cancer. Transplant Proc. 23, 2629-2631 (1991).
84. Podsypanina K, Du YC, Jechlinger M, Beverly LJ, Hambardzumyan D, Varmus H. Seeding and propagation of untransformed mouse mammary cells in the lung. Science 321, 1841-1844 (2008).
85. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 133, 571-573 (1889).
86. Sleeman JP, Nazarenko I, Thiele W. Do all roads lead to Rome? Routes to metastasis development. Int. J. Cancer 128, 2511-2526 (2011).
87. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 331, 1559-1564 (2011).
88. Tarin D. Cell and tissue interactions in carcinogenesis and metastasis and their clinical significance. Semin. Cancer Biol. 21, 72-82 (2011).
89. Tarin D. Clinical and biological Implications of the tumor microenvironment. Cancer Microenviron. 5, 95-112 (2012).
90. Tarin D. Inappropriate gene expression in human cancer and its far-reaching biological and clinical significance. Cancer Metastasis Rev. 31, 21-39 (2012).
91. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat. Med. 2, 461-462 (1996).
92. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J. Pathol. 189, 300-308 (1999).
93. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J. Pathol. 185, 256-261 (1998).
94. Murray GI, Duncan ME, Arbuckle E, Melvin WT, Fothergill JE. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 43, 791-797 (1998).
95. Curran S, Dundas SR, Buxton J, Leeman M, Ramsay R, Murray GI. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin. Cancer Res. 10, 8229-8234 (2004).
96. Lyall MS, Dundas SR, Curran S, Murray GI. Profiling markers of prognosis in colorectal cancer. Clin. Cancer Res. 12, 1184-1191 (2006).
97. Coghlin C, Carpenter B, Dundas SR, Lawrie LC, Telfer C, Murray GI. Characterisation and over-expression of chaperonin T-complex proteins in colorectal cancer. J. Pathol. 210, 351-357 (2006).
98. Jeffery N, Mclean MH, El-Omar EM, Murray GI. The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers. Histopathology 54, 820-828 (2009).
99. Duda DG, Duyverman AMMJ, Kohnoa M et al. Malignant cells facilitate lung metastasis by bringing their own soil. Proc. Natl Acad. Sci. USA 107, 21677-21682 (2010).
100. Comoglio PM, Trusolino L. Cancer: the matrix is now in control. Nat. Med. 11, 1156-1159 (2005).
101. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell. Biol. 196, 395-406 (2012).
102. Langley RR, Fidler IJ. The seed and soil hypothesis revisited\-The role of tumor-stroma interactions in metastasis to different organs. Int. J. Cancer 128, 2527-2535 (2011).
103. Coleman RE. Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy? Eur. J. Cancer 45, 1909-1905 (2009).
104. Coffey JC, Wang JH, Smith MJF, Bouchier-Hayes D, Cotter TG, Redmond HP. Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol. 12, 760-768 (2003).